The Balance of Cell Surface and Soluble Type III TGF-β Receptor Regulates BMP Signaling in Normal and Cancerous Mammary Epithelial Cells()

Por Gatza, Catherine E., Elderbroom, Jennifer L., Oh, Sun Young, Starr, Mark D., Nixon, Andrew B., Blobe, Gerard C.
Publicado em 2014

Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth

Por Knelson, Erik H., Gaviglio, Angela L., Nee, Jasmine C., Starr, Mark D., Nixon, Andrew B., Marcus, Stephen G., Blobe, Gerard C.
Publicado em 2014

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab

Por Liu, Yingmiao, Starr, Mark D, Bulusu, Anuradha, Pang, Herbert, Wong, Nan Soon, Honeycutt, Wanda, Amara, Anthony, Hurwitz, Herbert I, Nixon, Andrew B
Publicado em 2013

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

Por Teoh, Deanna, Ayeni, Tina A., Rubatt, Jennifer M., Adams, David J., Grace, Lisa, Starr, Mark D., Barry, William T, Berchuck, Andrew, Murphy, Susan K., Secord, Angeles Alvarez
Publicado em 2011

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

Por Liu, Yingmiao, Starr, Mark D, Brady, John C, Dellinger, Andrew, Pang, Herbert, Adams, Bonne, Theuer, Charles P, Lee, Nam Y, Hurwitz, Herbert I, Nixon, Andrew B
Publicado em 2014

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Por Nixon, Andrew B., Pang, Herbert, Starr, Mark D., Friedman, Paula N., Bertagnolli, Monica M., Kindler, Hedy L., Goldberg, Richard M., Venook, Alan P., Hurwitz, Herbert I.
Publicado no Clin Cancer Res (2013)

TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3

Por Hesler, Rachel A., Huang, Jennifer J., Starr, Mark D., Treboschi, Victoria M., Bernanke, Alyssa G., Nixon, Andrew B., McCall, Shannon J., White, Rebekah R., Blobe, Gerard C.
Publicado no Carcinogenesis (2016)

A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma

Por Bitting, Rhonda L., Healy, Patrick, Creel, Patricia A., Turnbull, James, Morris, Karla, Wood, Sarah Yenser, Hurwitz, Herbert I., Starr, Mark D., Nixon, Andrew B., Armstrong, Andrew J., George, Daniel J.
Publicado no Clin Genitourin Cancer (2013)

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

Por Uronis, Hope E, Cushman, Stephanie M, Bendell, Johanna C, Blobe, Gerard C, Morse, Michael A, Nixon, Andrew B, Dellinger, Andrew, Starr, Mark D, Li, Haiyan, Meadows, Kellen, Gockerman, Jon, Pang, Herbert, Hurwitz, Herbert I
Publicado em 2013

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

Por Hatch, Ace J., Sibley, Alexander B., Starr, Mark D., Brady, J. Chris, Jiang, Chen, Jia, Jingquan, Bowers, Daniel L., Pang, Herbert, Owzar, Kouros, Niedzwiecki, Donna, Innocenti, Federico, Venook, Alan P., Hurwitz, Herbert I., Nixon, Andrew B.
Publicado no Cancer Med (2016)